References
- Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain 1979; 6: 249.
- Stroup TS, Alves WM, Hamer RM, Lieberman JA. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov 2006; 5: 133-46. https://doi.org/10.1038/nrd1956
- Targum SD. Treating psychotic symptoms in elderly patients. Prim Care Companion J Clin Psychiatry 2001; 3: 156-63. https://doi.org/10.4088/PCC.v03n0402
- Leo RJ, Regno PD. Atypical antipsychotic use in the treatment of psychosis in primary care. Prim Care Companion J Clin Psychiatry 2000; 2: 194-204. https://doi.org/10.4088/PCC.v02n0601
- Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev 2008: CD004844.
- Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. J Pain Symptom Manage 2010; 39: 768-78. https://doi.org/10.1016/j.jpainsymman.2009.09.008
- Ramachandraiah CT, Subramaniam N, Tancer M. The story of antipsychotics: past and present. Indian J Psychiatry 2009; 51: 324-6. https://doi.org/10.4103/0019-5545.58304
- Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000; 57: 238-55. https://doi.org/10.1093/ajhp/57.3.238
- Gottfries CG, Green L. Flupenthixol decanoate--in treatment of out-patients. Acta Psychiatr Scand Suppl 1974; 255:15-24. https://doi.org/10.1111/j.1600-0447.1974.tb08890.x
- Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1081-90. https://doi.org/10.1016/j.pnpbp.2003.09.004
- Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull 2009; 35: 549-62. https://doi.org/10.1093/schbul/sbp006
- Yang AC, Tsai SJ. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci 2017; 18:1689. https://doi.org/10.3390/ijms18081689
- Inada T. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to i ts usage. Tokyo, Seiwa Shoten Publishers. 1996.
- Knol W, Keijsers CJ, Jansen PA, van Marum RJ. Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. J Clin Psychopharmacol 2010; 30: 57-63. https://doi.org/10.1097/JCP.0b013e3181c914b3
- Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005; 76: 247-65. https://doi.org/10.1016/j.schres.2005.02.013
- Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm 1997; 54: 2461-77. https://doi.org/10.1093/ajhp/54.21.2461
- Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28: 863-73. https://doi.org/10.1002/mds.25475
- Skogseid IM. Dystonia--new advances in classification, genetics, pathophysiology and treatment. Acta Neurol Scand 2014; 129: 13-9. https://doi.org/10.1111/ane.12231
- Kurlan R, Rabin M L. P seudoparkinsonism: a review of a common nonparkinsonian hypokinetic movement disorder. Adv Parkinson Dis 2013; 2: 108-12. https://doi.org/10.4236/apd.2013.24020
- Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54: 133-9.
- Munetz MR, Schulz SC. Screening for tardive dyskinesia. J Clin Psychiatry 1986; 47: 75-7.
- Uhlyar S, Rey JA. Valbenazine (Ingrezza): the first FDAapproved treatment for tardive dyskinesia. P T 2018; 43: 328-31.
- Markowitz JD, Narasimhan M. Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgmont) 2008; 5: 29-36. https://doi.org/10.1383/psyt.2006.5.1.29
- Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47: 27-38.
- Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61: 16-21. https://doi.org/10.4088/JCP.v61n0105
- Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004; 6: 3-7. https://doi.org/10.4088/PCC.v06n0101
- Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 2006; 40: 626-32. https://doi.org/10.1345/aph.1G564
- Gentile S. Contributing factors to weight gain during longterm treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev 2009; 10: 527-42. https://doi.org/10.1111/j.1467-789X.2009.00589.x
- Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychoticinduced weight gain: insights into mechanisms of action. CNS Drugs 2011; 25: 1035-59. https://doi.org/10.2165/11596300-000000000-00000
- Taylor DM, McAskill R. Atypical antipsychotics and weight gain--a systematic review. Acta Psychiatr Scand 2000; 101: 416-32. https://doi.org/10.1034/j.1600-0447.2000.101006416.x
- Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 2004; 37: 1-11.
- Schwenkreis P, Assion HJ. Atypical antipsychotics and diabetes mellitus. World J Biol Psychiatry 2004; 5: 73-82. https://doi.org/10.1080/15622970410029915
- Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62: 15-26.
- Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 2014; 40: 314-26. https://doi.org/10.1093/schbul/sbu001
- Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Cipriani A, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 2015; 41: 1397-402. https://doi.org/10.1093/schbul/sbv037
- Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-7. https://doi.org/10.4088/JCP.v64n0607
- Khouzam HR. Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics. Postgrad Med 2016; 128: 323-30. https://doi.org/10.1080/00325481.2016.1147925
- Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172: 1703-11. https://doi.org/10.1503/cmaj.1041064